Newly manufactured plasmids will be applied in clinical trials evaluating Oncoprex in combination with targeted therapies and immunotherapies
Austin, Texas, Cambridge, Mass. and Fargo, N.D. – September 26, 2018 – Genprex, Inc. (NASDAQ: GNPX), a clinical stage gene therapy company developing a new approach to treating cancer based upon a novel proprietary technology platform, has signed an agreement with Aldevron, a leading contract manufacturing organization, to supply TUSC2 (Tumor Suppressor Candidate2) plasmid DNA for use in Genprex’s clinical development program evaluating its immunogene therapy Oncoprex for the treatment of non-small cell lung cancer.
“Plasmid DNA plays an important role in the delivery of gene therapies into target cells,” said Rodney Varner, Chairman and Chief Executive Officer of Genprex. “Aldevron is a leading plasmid manufacturer that offers world-class laboratory and manufacturing programs. Through this agreement, we have established a GMP-validated supply of plasmid DNA vectors for our expanding clinical program evaluating the utility of Oncoprex in combination with some of the most promising new therapies for cancer.”
“Aldevron is honored to partner with Genprex in the development of Oncoprex,” said Michael Chambers, CEO of Aldevron. “This collaboration furthers our goal to provide high-quality plasmid DNA and other biologics to leading companies such as Genprex that are creating treatments that could have a significant impact on human health.”
Aldevron serves the biotechnology industry with custom production of nucleic acids, proteins, and antibodies. Thousands of clients use Aldevron-produced plasmids, RNA and gene editing enzymes for projects ranging from discovery research to clinical trials to commercial applications. These products are critical raw materials and key components in commercially available drugs and medical devices. Aldevron specializes in GMP manufacturing and is known for inventing the GMP-SourceTM quality system. Company headquarters are in Fargo, North Dakota, with additional facilities in Madison, Wisconsin, and Freiburg, Germany.
About Genprex™, Inc.
Genprex, Inc. is a clinical stage gene therapy company developing a new approach to treating cancer, based upon a novel proprietary technology platform, including Genprex’s initial product candidate, Oncoprex™ immunogene therapy for non-small cell lung cancer (NSCLC). Genprex’s platform technologies are designed to administer cancer fighting genes by encapsulating them into nanoscale hollow spheres called nanovesicles, which are then administered intravenously and taken up by tumor cells where they express proteins that are missing or found in low quantities. Oncoprex has a multimodal mechanism of action whereby it interrupts cell signaling pathways that cause replication and proliferation of cancer cells, re-establishes pathways for apoptosis, or programmed cell death, in cancer cells, and modulates the immune response against cancer cells. Oncoprex has also been shown to block mechanisms that create drug resistance.